Market Overview

UPDATE: Jefferies Raises PT to $25 on Insulet Following Eros FDA Approval

Share:
Related PODD
Letter To Massachusetts Attorney General Outlines Undisclosed Insulet Omnipod Patient Deaths
New Report Questions Insulet Management's 'Baseless' Claims: 'Investors Being Led To The Slaughter'

Jefferies reiterated its Buy rating on Insulet (NASDAQ: PODD) and increased its price target from $23 to $25.

Jefferies said, "Insulet announced approval of the Eros pod this morning, bringing a close an almost two year 510k approval process. Insulet estimates it will take 45-60 days to educate customers and scale up to a full launch, which puts the beginning of the transition from the legacy pod to Eros in March. The company has stockpiled approximately 6-7 weeks of inventory with the current pod to enable a quick transition to Eros manufacturing."

Insulet closed at $21.85 on Friday.

Latest Ratings for PODD

DateFirmActionFromTo
Nov 2016BTIG ResearchUpgradesNeutralBuy
Sep 2016B. RileyInitiates Coverage onNeutral
Aug 2016JefferiesMaintainsBuy

View More Analyst Ratings for PODD
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (PODD)

View Comments and Join the Discussion!